nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—Myelosuppression—Vinblastine—head and neck cancer	0.00875	0.0742	CcSEcCtD
Ruxolitinib—Myelosuppression—Hydroxyurea—head and neck cancer	0.00798	0.0677	CcSEcCtD
Ruxolitinib—LTK—tongue—head and neck cancer	0.00773	0.0252	CbGeAlD
Ruxolitinib—RET—parathyroid gland—head and neck cancer	0.00741	0.0242	CbGeAlD
Ruxolitinib—Myelosuppression—Fluorouracil—head and neck cancer	0.00575	0.0487	CcSEcCtD
Ruxolitinib—JAK1—hair follicle—head and neck cancer	0.00526	0.0172	CbGeAlD
Ruxolitinib—LTK—mouth—head and neck cancer	0.0052	0.017	CbGeAlD
Ruxolitinib—CLK2—hair follicle—head and neck cancer	0.00467	0.0153	CbGeAlD
Ruxolitinib—DYRK1A—hair follicle—head and neck cancer	0.00442	0.0144	CbGeAlD
Ruxolitinib—Bone pain—Vinblastine—head and neck cancer	0.00428	0.0363	CcSEcCtD
Ruxolitinib—Myelosuppression—Docetaxel—head and neck cancer	0.00415	0.0352	CcSEcCtD
Ruxolitinib—JAK1—neck—head and neck cancer	0.00353	0.0115	CbGeAlD
Ruxolitinib—MKNK2—hair follicle—head and neck cancer	0.00343	0.0112	CbGeAlD
Ruxolitinib—IRAK1—hair follicle—head and neck cancer	0.00343	0.0112	CbGeAlD
Ruxolitinib—GRK7—head—head and neck cancer	0.00342	0.0112	CbGeAlD
Ruxolitinib—ANKK1—head—head and neck cancer	0.00313	0.0102	CbGeAlD
Ruxolitinib—PLK1—lymphoid tissue—head and neck cancer	0.00289	0.00943	CbGeAlD
Ruxolitinib—JAK1—parotid gland—head and neck cancer	0.00287	0.00939	CbGeAlD
Ruxolitinib—PLK3—trachea—head and neck cancer	0.00277	0.00904	CbGeAlD
Ruxolitinib—JAK1—saliva-secreting gland—head and neck cancer	0.00275	0.00899	CbGeAlD
Ruxolitinib—DAPK2—parotid gland—head and neck cancer	0.00274	0.00895	CbGeAlD
Ruxolitinib—PRKCE—thyroid gland—head and neck cancer	0.00273	0.00892	CbGeAlD
Ruxolitinib—BMP2K—neck—head and neck cancer	0.00264	0.00863	CbGeAlD
Ruxolitinib—DAPK2—saliva-secreting gland—head and neck cancer	0.00263	0.00857	CbGeAlD
Ruxolitinib—RPS6KA6—thyroid gland—head and neck cancer	0.00262	0.00857	CbGeAlD
Ruxolitinib—PRKG2—head—head and neck cancer	0.00259	0.00847	CbGeAlD
Ruxolitinib—CLK2—parotid gland—head and neck cancer	0.00255	0.00834	CbGeAlD
Ruxolitinib—JAK3—connective tissue—head and neck cancer	0.00255	0.00831	CbGeAlD
Ruxolitinib—JAK1—connective tissue—head and neck cancer	0.00253	0.00826	CbGeAlD
Ruxolitinib—GRK1—head—head and neck cancer	0.00248	0.00808	CbGeAlD
Ruxolitinib—CLK2—saliva-secreting gland—head and neck cancer	0.00245	0.00799	CbGeAlD
Ruxolitinib—Pancytopenia—Vinblastine—head and neck cancer	0.00245	0.0207	CcSEcCtD
Ruxolitinib—PRKCE—head—head and neck cancer	0.00242	0.00791	CbGeAlD
Ruxolitinib—JAK1—epithelium—head and neck cancer	0.0024	0.00784	CbGeAlD
Ruxolitinib—HIPK2—connective tissue—head and neck cancer	0.00236	0.00771	CbGeAlD
Ruxolitinib—RPS6KA6—head—head and neck cancer	0.00233	0.0076	CbGeAlD
Ruxolitinib—PLK1—head—head and neck cancer	0.00233	0.0076	CbGeAlD
Ruxolitinib—MAST1—head—head and neck cancer	0.00233	0.0076	CbGeAlD
Ruxolitinib—NUAK2—parotid gland—head and neck cancer	0.0023	0.0075	CbGeAlD
Ruxolitinib—RET—neck—head and neck cancer	0.00225	0.00733	CbGeAlD
Ruxolitinib—Pancytopenia—Hydroxyurea—head and neck cancer	0.00223	0.0189	CcSEcCtD
Ruxolitinib—DCLK3—head—head and neck cancer	0.00221	0.0072	CbGeAlD
Ruxolitinib—NUAK2—saliva-secreting gland—head and neck cancer	0.0022	0.00719	CbGeAlD
Ruxolitinib—Neutropenia—Hydroxyurea—head and neck cancer	0.0022	0.0186	CcSEcCtD
Ruxolitinib—PLK3—thyroid gland—head and neck cancer	0.00219	0.00715	CbGeAlD
Ruxolitinib—ROCK1—connective tissue—head and neck cancer	0.00218	0.00711	CbGeAlD
Ruxolitinib—Weight increased—Hydroxyurea—head and neck cancer	0.00214	0.0181	CcSEcCtD
Ruxolitinib—JAK1—trachea—head and neck cancer	0.00212	0.00693	CbGeAlD
Ruxolitinib—DCLK1—trachea—head and neck cancer	0.00212	0.00693	CbGeAlD
Ruxolitinib—BMPR2—connective tissue—head and neck cancer	0.00212	0.00691	CbGeAlD
Ruxolitinib—Infestation NOS—Hydroxyurea—head and neck cancer	0.00209	0.0178	CcSEcCtD
Ruxolitinib—Infestation—Hydroxyurea—head and neck cancer	0.00209	0.0178	CcSEcCtD
Ruxolitinib—CAMK1D—trachea—head and neck cancer	0.00207	0.00677	CbGeAlD
Ruxolitinib—Haemoglobin—Vinblastine—head and neck cancer	0.00207	0.0176	CcSEcCtD
Ruxolitinib—ROCK1—epithelium—head and neck cancer	0.00207	0.00675	CbGeAlD
Ruxolitinib—Haemorrhage—Vinblastine—head and neck cancer	0.00206	0.0175	CcSEcCtD
Ruxolitinib—CAMK1—thyroid gland—head and neck cancer	0.00205	0.00669	CbGeAlD
Ruxolitinib—Bone pain—Docetaxel—head and neck cancer	0.00203	0.0172	CcSEcCtD
Ruxolitinib—DAPK2—trachea—head and neck cancer	0.00203	0.00661	CbGeAlD
Ruxolitinib—MARK2—thyroid gland—head and neck cancer	0.00199	0.00649	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00198	0.0168	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.00196	0.0166	CcSEcCtD
Ruxolitinib—PLK3—head—head and neck cancer	0.00194	0.00634	CbGeAlD
Ruxolitinib—MAP3K7—parotid gland—head and neck cancer	0.00194	0.00632	CbGeAlD
Ruxolitinib—TYK2—parotid gland—head and neck cancer	0.0019	0.00621	CbGeAlD
Ruxolitinib—BMP2K—connective tissue—head and neck cancer	0.00189	0.00618	CbGeAlD
Ruxolitinib—Haemoglobin—Hydroxyurea—head and neck cancer	0.00189	0.016	CcSEcCtD
Ruxolitinib—CLK2—trachea—head and neck cancer	0.00189	0.00616	CbGeAlD
Ruxolitinib—Haemorrhage—Hydroxyurea—head and neck cancer	0.00188	0.0159	CcSEcCtD
Ruxolitinib—LTK—head—head and neck cancer	0.00188	0.00613	CbGeAlD
Ruxolitinib—MKNK2—parotid gland—head and neck cancer	0.00188	0.00612	CbGeAlD
Ruxolitinib—JAK3—lymphoid tissue—head and neck cancer	0.00186	0.00608	CbGeAlD
Ruxolitinib—MAP3K7—saliva-secreting gland—head and neck cancer	0.00185	0.00605	CbGeAlD
Ruxolitinib—JAK1—lymphoid tissue—head and neck cancer	0.00185	0.00604	CbGeAlD
Ruxolitinib—TAOK2—thyroid gland—head and neck cancer	0.00184	0.00601	CbGeAlD
Ruxolitinib—PLK4—lymphoid tissue—head and neck cancer	0.00184	0.006	CbGeAlD
Ruxolitinib—TYK2—saliva-secreting gland—head and neck cancer	0.00182	0.00594	CbGeAlD
Ruxolitinib—CAMK1—head—head and neck cancer	0.00182	0.00593	CbGeAlD
Ruxolitinib—MKNK2—saliva-secreting gland—head and neck cancer	0.0018	0.00587	CbGeAlD
Ruxolitinib—MARK2—head—head and neck cancer	0.00176	0.00576	CbGeAlD
Ruxolitinib—STK16—lymphoid tissue—head and neck cancer	0.00174	0.00567	CbGeAlD
Ruxolitinib—HIPK2—lymphoid tissue—head and neck cancer	0.00173	0.00564	CbGeAlD
Ruxolitinib—MAP3K2—connective tissue—head and neck cancer	0.00172	0.00561	CbGeAlD
Ruxolitinib—NUAK2—trachea—head and neck cancer	0.0017	0.00554	CbGeAlD
Ruxolitinib—PRKCE—lymph node—head and neck cancer	0.0017	0.00554	CbGeAlD
Ruxolitinib—JAK3—thyroid gland—head and neck cancer	0.00169	0.00552	CbGeAlD
Ruxolitinib—DCLK1—thyroid gland—head and neck cancer	0.00168	0.00549	CbGeAlD
Ruxolitinib—JAK1—thyroid gland—head and neck cancer	0.00168	0.00549	CbGeAlD
Ruxolitinib—TYK2—connective tissue—head and neck cancer	0.00167	0.00546	CbGeAlD
Ruxolitinib—MAP3K3—parotid gland—head and neck cancer	0.00167	0.00544	CbGeAlD
Ruxolitinib—Anaemia—Vinblastine—head and neck cancer	0.00166	0.0141	CcSEcCtD
Ruxolitinib—MKNK2—connective tissue—head and neck cancer	0.00165	0.00539	CbGeAlD
Ruxolitinib—CLK2—lymphoid tissue—head and neck cancer	0.00164	0.00537	CbGeAlD
Ruxolitinib—CAMK1D—thyroid gland—head and neck cancer	0.00164	0.00535	CbGeAlD
Ruxolitinib—PHKG2—thyroid gland—head and neck cancer	0.00163	0.00532	CbGeAlD
Ruxolitinib—RPS6KA6—lymph node—head and neck cancer	0.00163	0.00532	CbGeAlD
Ruxolitinib—PLK1—lymph node—head and neck cancer	0.00163	0.00532	CbGeAlD
Ruxolitinib—RET—connective tissue—head and neck cancer	0.00161	0.00526	CbGeAlD
Ruxolitinib—Pancytopenia—Fluorouracil—head and neck cancer	0.00161	0.0136	CcSEcCtD
Ruxolitinib—DAPK2—thyroid gland—head and neck cancer	0.0016	0.00523	CbGeAlD
Ruxolitinib—MAP3K3—saliva-secreting gland—head and neck cancer	0.0016	0.00521	CbGeAlD
Ruxolitinib—ROCK1—lymphoid tissue—head and neck cancer	0.00159	0.0052	CbGeAlD
Ruxolitinib—STK16—thyroid gland—head and neck cancer	0.00158	0.00515	CbGeAlD
Ruxolitinib—HIPK2—thyroid gland—head and neck cancer	0.00157	0.00512	CbGeAlD
Ruxolitinib—MKNK2—epithelium—head and neck cancer	0.00157	0.00512	CbGeAlD
Ruxolitinib—DYRK1A—lymphoid tissue—head and neck cancer	0.00155	0.00507	CbGeAlD
Ruxolitinib—BMPR2—lymphoid tissue—head and neck cancer	0.00155	0.00505	CbGeAlD
Ruxolitinib—RET—epithelium—head and neck cancer	0.00153	0.00499	CbGeAlD
Ruxolitinib—JAK2—connective tissue—head and neck cancer	0.00152	0.00497	CbGeAlD
Ruxolitinib—TAOK3—parotid gland—head and neck cancer	0.00152	0.00496	CbGeAlD
Ruxolitinib—Anaemia—Hydroxyurea—head and neck cancer	0.00151	0.0128	CcSEcCtD
Ruxolitinib—Infestation—Fluorouracil—head and neck cancer	0.00151	0.0128	CcSEcCtD
Ruxolitinib—Infestation NOS—Fluorouracil—head and neck cancer	0.00151	0.0128	CcSEcCtD
Ruxolitinib—DAPK3—thyroid gland—head and neck cancer	0.00151	0.00492	CbGeAlD
Ruxolitinib—JAK3—head—head and neck cancer	0.0015	0.0049	CbGeAlD
Ruxolitinib—CLK2—thyroid gland—head and neck cancer	0.00149	0.00487	CbGeAlD
Ruxolitinib—JAK1—head—head and neck cancer	0.00149	0.00487	CbGeAlD
Ruxolitinib—DCLK1—head—head and neck cancer	0.00149	0.00487	CbGeAlD
Ruxolitinib—Urinary tract infection—Fluorouracil—head and neck cancer	0.00146	0.0124	CcSEcCtD
Ruxolitinib—TAOK3—saliva-secreting gland—head and neck cancer	0.00146	0.00475	CbGeAlD
Ruxolitinib—CAMK1D—head—head and neck cancer	0.00145	0.00475	CbGeAlD
Ruxolitinib—PHKG2—head—head and neck cancer	0.00145	0.00472	CbGeAlD
Ruxolitinib—JAK2—epithelium—head and neck cancer	0.00144	0.00472	CbGeAlD
Ruxolitinib—Thrombocytopenia—Vinblastine—head and neck cancer	0.00143	0.0122	CcSEcCtD
Ruxolitinib—MAP3K7—trachea—head and neck cancer	0.00143	0.00467	CbGeAlD
Ruxolitinib—Epistaxis—Fluorouracil—head and neck cancer	0.00142	0.0121	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.00141	0.012	CcSEcCtD
Ruxolitinib—DYRK1A—thyroid gland—head and neck cancer	0.00141	0.00461	CbGeAlD
Ruxolitinib—BMPR2—thyroid gland—head and neck cancer	0.00141	0.00459	CbGeAlD
Ruxolitinib—TYK2—trachea—head and neck cancer	0.0014	0.00458	CbGeAlD
Ruxolitinib—STK16—head—head and neck cancer	0.0014	0.00457	CbGeAlD
Ruxolitinib—HIPK2—head—head and neck cancer	0.00139	0.00454	CbGeAlD
Ruxolitinib—MKNK2—trachea—head and neck cancer	0.00139	0.00453	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00138	0.0117	CcSEcCtD
Ruxolitinib—MAP3K19—head—head and neck cancer	0.00136	0.00445	CbGeAlD
Ruxolitinib—PLK3—lymph node—head and neck cancer	0.00136	0.00444	CbGeAlD
Ruxolitinib—Haemoglobin—Fluorouracil—head and neck cancer	0.00136	0.0115	CcSEcCtD
Ruxolitinib—Haemorrhage—Fluorouracil—head and neck cancer	0.00135	0.0115	CcSEcCtD
Ruxolitinib—NUAK2—thyroid gland—head and neck cancer	0.00134	0.00439	CbGeAlD
Ruxolitinib—TAOK3—connective tissue—head and neck cancer	0.00134	0.00437	CbGeAlD
Ruxolitinib—DAPK3—head—head and neck cancer	0.00134	0.00436	CbGeAlD
Ruxolitinib—Infection—Hydroxyurea—head and neck cancer	0.00133	0.0113	CcSEcCtD
Ruxolitinib—CLK2—head—head and neck cancer	0.00132	0.00432	CbGeAlD
Ruxolitinib—LTK—lymph node—head and neck cancer	0.00131	0.00429	CbGeAlD
Ruxolitinib—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00131	0.0111	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.00131	0.0111	CcSEcCtD
Ruxolitinib—Skin disorder—Hydroxyurea—head and neck cancer	0.0013	0.011	CcSEcCtD
Ruxolitinib—ROCK1—head—head and neck cancer	0.00128	0.00419	CbGeAlD
Ruxolitinib—JAK2—trachea—head and neck cancer	0.00128	0.00417	CbGeAlD
Ruxolitinib—CAMK1—lymph node—head and neck cancer	0.00127	0.00415	CbGeAlD
Ruxolitinib—CAMK2G—thyroid gland—head and neck cancer	0.00126	0.00411	CbGeAlD
Ruxolitinib—BMP2K—thyroid gland—head and neck cancer	0.00126	0.00411	CbGeAlD
Ruxolitinib—MAP3K2—lymphoid tissue—head and neck cancer	0.00126	0.00411	CbGeAlD
Ruxolitinib—DYRK1A—head—head and neck cancer	0.00125	0.00409	CbGeAlD
Ruxolitinib—BMPR2—head—head and neck cancer	0.00125	0.00407	CbGeAlD
Ruxolitinib—LRRK2—thyroid gland—head and neck cancer	0.00125	0.00407	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.00124	0.0106	CcSEcCtD
Ruxolitinib—MARK2—lymph node—head and neck cancer	0.00124	0.00403	CbGeAlD
Ruxolitinib—MAP3K3—trachea—head and neck cancer	0.00123	0.00402	CbGeAlD
Ruxolitinib—TYK2—lymphoid tissue—head and neck cancer	0.00122	0.00399	CbGeAlD
Ruxolitinib—MKNK2—lymphoid tissue—head and neck cancer	0.00121	0.00394	CbGeAlD
Ruxolitinib—RET—lymphoid tissue—head and neck cancer	0.00118	0.00384	CbGeAlD
Ruxolitinib—Pancytopenia—Docetaxel—head and neck cancer	0.00116	0.00983	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00115	0.00978	CcSEcCtD
Ruxolitinib—Fatigue—Hydroxyurea—head and neck cancer	0.00115	0.00977	CcSEcCtD
Ruxolitinib—TAOK2—lymph node—head and neck cancer	0.00114	0.00373	CbGeAlD
Ruxolitinib—MAP3K2—thyroid gland—head and neck cancer	0.00114	0.00373	CbGeAlD
Ruxolitinib—Neutropenia—Docetaxel—head and neck cancer	0.00114	0.00968	CcSEcCtD
Ruxolitinib—MAP3K7—thyroid gland—head and neck cancer	0.00113	0.00369	CbGeAlD
Ruxolitinib—TAOK3—trachea—head and neck cancer	0.00112	0.00367	CbGeAlD
Ruxolitinib—CAMK2G—head—head and neck cancer	0.00112	0.00364	CbGeAlD
Ruxolitinib—BMP2K—head—head and neck cancer	0.00112	0.00364	CbGeAlD
Ruxolitinib—JAK2—lymphoid tissue—head and neck cancer	0.00111	0.00363	CbGeAlD
Ruxolitinib—TYK2—thyroid gland—head and neck cancer	0.00111	0.00363	CbGeAlD
Ruxolitinib—Weight increased—Docetaxel—head and neck cancer	0.00111	0.00942	CcSEcCtD
Ruxolitinib—LRRK2—head—head and neck cancer	0.00111	0.00361	CbGeAlD
Ruxolitinib—Weight decreased—Docetaxel—head and neck cancer	0.0011	0.00936	CcSEcCtD
Ruxolitinib—MKNK2—thyroid gland—head and neck cancer	0.0011	0.00358	CbGeAlD
Ruxolitinib—IRAK1—thyroid gland—head and neck cancer	0.0011	0.00358	CbGeAlD
Ruxolitinib—Anaemia—Fluorouracil—head and neck cancer	0.00109	0.00923	CcSEcCtD
Ruxolitinib—Infestation NOS—Docetaxel—head and neck cancer	0.00109	0.00923	CcSEcCtD
Ruxolitinib—Infestation—Docetaxel—head and neck cancer	0.00109	0.00923	CcSEcCtD
Ruxolitinib—RET—thyroid gland—head and neck cancer	0.00107	0.00349	CbGeAlD
Ruxolitinib—Body temperature increased—Hydroxyurea—head and neck cancer	0.00106	0.00895	CcSEcCtD
Ruxolitinib—Asthenia—Vinblastine—head and neck cancer	0.00105	0.00891	CcSEcCtD
Ruxolitinib—JAK3—lymph node—head and neck cancer	0.00105	0.00343	CbGeAlD
Ruxolitinib—JAK1—lymph node—head and neck cancer	0.00104	0.00341	CbGeAlD
Ruxolitinib—DCLK1—lymph node—head and neck cancer	0.00104	0.00341	CbGeAlD
Ruxolitinib—PLK4—lymph node—head and neck cancer	0.00104	0.00339	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Docetaxel—head and neck cancer	0.00103	0.00873	CcSEcCtD
Ruxolitinib—Epistaxis—Docetaxel—head and neck cancer	0.00103	0.0087	CcSEcCtD
Ruxolitinib—CAMK1D—lymph node—head and neck cancer	0.00102	0.00333	CbGeAlD
Ruxolitinib—MAP3K2—head—head and neck cancer	0.00101	0.00331	CbGeAlD
Ruxolitinib—PHKG2—lymph node—head and neck cancer	0.00101	0.00331	CbGeAlD
Ruxolitinib—JAK2—thyroid gland—head and neck cancer	0.00101	0.0033	CbGeAlD
Ruxolitinib—DAPK2—lymph node—head and neck cancer	0.000995	0.00325	CbGeAlD
Ruxolitinib—TYK2—head—head and neck cancer	0.000985	0.00322	CbGeAlD
Ruxolitinib—Haemoglobin—Docetaxel—head and neck cancer	0.000981	0.00832	CcSEcCtD
Ruxolitinib—STK16—lymph node—head and neck cancer	0.000979	0.0032	CbGeAlD
Ruxolitinib—TAOK3—lymphoid tissue—head and neck cancer	0.000978	0.00319	CbGeAlD
Ruxolitinib—Haemorrhage—Docetaxel—head and neck cancer	0.000976	0.00828	CcSEcCtD
Ruxolitinib—HIPK2—lymph node—head and neck cancer	0.000974	0.00318	CbGeAlD
Ruxolitinib—MAP3K3—thyroid gland—head and neck cancer	0.000974	0.00318	CbGeAlD
Ruxolitinib—MKNK2—head—head and neck cancer	0.000973	0.00318	CbGeAlD
Ruxolitinib—Dizziness—Vinblastine—head and neck cancer	0.000968	0.00821	CcSEcCtD
Ruxolitinib—Asthenia—Hydroxyurea—head and neck cancer	0.000958	0.00813	CcSEcCtD
Ruxolitinib—Infection—Fluorouracil—head and neck cancer	0.000955	0.0081	CcSEcCtD
Ruxolitinib—RET—head—head and neck cancer	0.000949	0.0031	CbGeAlD
Ruxolitinib—Nervous system disorder—Fluorouracil—head and neck cancer	0.000943	0.008	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000941	0.00798	CcSEcCtD
Ruxolitinib—DAPK3—lymph node—head and neck cancer	0.000936	0.00306	CbGeAlD
Ruxolitinib—CLK2—lymph node—head and neck cancer	0.000927	0.00303	CbGeAlD
Ruxolitinib—Headache—Vinblastine—head and neck cancer	0.000917	0.00778	CcSEcCtD
Ruxolitinib—JAK2—head—head and neck cancer	0.000897	0.00293	CbGeAlD
Ruxolitinib—TAOK3—thyroid gland—head and neck cancer	0.000888	0.0029	CbGeAlD
Ruxolitinib—Dizziness—Hydroxyurea—head and neck cancer	0.000883	0.00749	CcSEcCtD
Ruxolitinib—DYRK1A—lymph node—head and neck cancer	0.000876	0.00286	CbGeAlD
Ruxolitinib—BMPR2—lymph node—head and neck cancer	0.000873	0.00285	CbGeAlD
Ruxolitinib—MAP3K3—head—head and neck cancer	0.000864	0.00282	CbGeAlD
Ruxolitinib—Malnutrition—Docetaxel—head and neck cancer	0.00085	0.00721	CcSEcCtD
Ruxolitinib—Headache—Hydroxyurea—head and neck cancer	0.000837	0.0071	CcSEcCtD
Ruxolitinib—NUAK2—lymph node—head and neck cancer	0.000834	0.00272	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00083	0.00704	CcSEcCtD
Ruxolitinib—TAOK3—head—head and neck cancer	0.000788	0.00257	CbGeAlD
Ruxolitinib—Anaemia—Docetaxel—head and neck cancer	0.000786	0.00666	CcSEcCtD
Ruxolitinib—CAMK2G—lymph node—head and neck cancer	0.000781	0.00255	CbGeAlD
Ruxolitinib—BMP2K—lymph node—head and neck cancer	0.000781	0.00255	CbGeAlD
Ruxolitinib—LRRK2—lymph node—head and neck cancer	0.000774	0.00253	CbGeAlD
Ruxolitinib—Body temperature increased—Fluorouracil—head and neck cancer	0.00076	0.00645	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000719	0.0061	CcSEcCtD
Ruxolitinib—MAP3K2—lymph node—head and neck cancer	0.000709	0.00232	CbGeAlD
Ruxolitinib—MAP3K7—lymph node—head and neck cancer	0.000703	0.00229	CbGeAlD
Ruxolitinib—TYK2—lymph node—head and neck cancer	0.00069	0.00225	CbGeAlD
Ruxolitinib—Infection—Docetaxel—head and neck cancer	0.000689	0.00585	CcSEcCtD
Ruxolitinib—IRAK1—lymph node—head and neck cancer	0.000681	0.00222	CbGeAlD
Ruxolitinib—MKNK2—lymph node—head and neck cancer	0.000681	0.00222	CbGeAlD
Ruxolitinib—Nervous system disorder—Docetaxel—head and neck cancer	0.00068	0.00577	CcSEcCtD
Ruxolitinib—Pruritus—Fluorouracil—head and neck cancer	0.00068	0.00577	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Docetaxel—head and neck cancer	0.000679	0.00576	CcSEcCtD
Ruxolitinib—Skin disorder—Docetaxel—head and neck cancer	0.000674	0.00572	CcSEcCtD
Ruxolitinib—RET—lymph node—head and neck cancer	0.000664	0.00217	CbGeAlD
Ruxolitinib—Dizziness—Fluorouracil—head and neck cancer	0.000636	0.00539	CcSEcCtD
Ruxolitinib—JAK2—lymph node—head and neck cancer	0.000628	0.00205	CbGeAlD
Ruxolitinib—MAP3K3—lymph node—head and neck cancer	0.000605	0.00198	CbGeAlD
Ruxolitinib—Headache—Fluorouracil—head and neck cancer	0.000602	0.00511	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000599	0.00508	CcSEcCtD
Ruxolitinib—Fatigue—Docetaxel—head and neck cancer	0.000598	0.00507	CcSEcCtD
Ruxolitinib—TAOK3—lymph node—head and neck cancer	0.000552	0.0018	CbGeAlD
Ruxolitinib—Body temperature increased—Docetaxel—head and neck cancer	0.000548	0.00465	CcSEcCtD
Ruxolitinib—Asthenia—Docetaxel—head and neck cancer	0.000498	0.00422	CcSEcCtD
Ruxolitinib—Pruritus—Docetaxel—head and neck cancer	0.000491	0.00416	CcSEcCtD
Ruxolitinib—Dizziness—Docetaxel—head and neck cancer	0.000459	0.00389	CcSEcCtD
Ruxolitinib—Headache—Docetaxel—head and neck cancer	0.000435	0.00369	CcSEcCtD
Ruxolitinib—ROCK1—Signaling by GPCR—MAPK1—head and neck cancer	2.07e-05	3.6e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—EGFR—head and neck cancer	2.07e-05	3.6e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—AKT1—head and neck cancer	2.07e-05	3.6e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—PIK3CA—head and neck cancer	2.06e-05	3.58e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—AKT1—head and neck cancer	2.06e-05	3.57e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—MAPK1—head and neck cancer	2.05e-05	3.57e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—PIK3CA—head and neck cancer	2.05e-05	3.57e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—BCL2—head and neck cancer	2.05e-05	3.56e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL2—head and neck cancer	2.03e-05	3.53e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—MAPK3—head and neck cancer	2.02e-05	3.51e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—HRAS—head and neck cancer	2.02e-05	3.51e-05	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—PIK3CA—head and neck cancer	2.01e-05	3.5e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—PIK3CA—head and neck cancer	1.98e-05	3.44e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—PIK3CA—head and neck cancer	1.97e-05	3.43e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—HRAS—head and neck cancer	1.97e-05	3.42e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—HRAS—head and neck cancer	1.97e-05	3.41e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—HRAS—head and neck cancer	1.96e-05	3.4e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—AKT1—head and neck cancer	1.96e-05	3.4e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—STAT3—head and neck cancer	1.96e-05	3.4e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—HRAS—head and neck cancer	1.95e-05	3.39e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—MAPK3—head and neck cancer	1.94e-05	3.38e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—PIK3CA—head and neck cancer	1.94e-05	3.37e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—MAPK1—head and neck cancer	1.93e-05	3.34e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—EGFR—head and neck cancer	1.93e-05	3.34e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL2—head and neck cancer	1.91e-05	3.32e-05	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—AKT1—head and neck cancer	1.91e-05	3.32e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—VEGFA—head and neck cancer	1.91e-05	3.31e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—HRAS—head and neck cancer	1.91e-05	3.31e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—HRAS—head and neck cancer	1.9e-05	3.3e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL2—head and neck cancer	1.89e-05	3.29e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NOTCH1—head and neck cancer	1.89e-05	3.28e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—STAT3—head and neck cancer	1.89e-05	3.28e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—AKT1—head and neck cancer	1.88e-05	3.27e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—AKT1—head and neck cancer	1.87e-05	3.25e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—MAPK3—head and neck cancer	1.87e-05	3.24e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CASP8—head and neck cancer	1.86e-05	3.24e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL2—head and neck cancer	1.86e-05	3.23e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PTGS2—head and neck cancer	1.85e-05	3.21e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—MAPK1—head and neck cancer	1.85e-05	3.21e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—EGFR—head and neck cancer	1.85e-05	3.21e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CCND1—head and neck cancer	1.84e-05	3.2e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CDH1—head and neck cancer	1.84e-05	3.2e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—PIK3CA—head and neck cancer	1.83e-05	3.18e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—HRAS—head and neck cancer	1.83e-05	3.17e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL2—head and neck cancer	1.8e-05	3.13e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MAPK3—head and neck cancer	1.8e-05	3.13e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—PTEN—head and neck cancer	1.8e-05	3.13e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—PIK3CA—head and neck cancer	1.8e-05	3.12e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NOTCH1—head and neck cancer	1.8e-05	3.12e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—HRAS—head and neck cancer	1.8e-05	3.12e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—PIK3CA—head and neck cancer	1.78e-05	3.1e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—AKT1—head and neck cancer	1.78e-05	3.1e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PTEN—head and neck cancer	1.78e-05	3.09e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—MAPK1—head and neck cancer	1.78e-05	3.09e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—EGFR—head and neck cancer	1.78e-05	3.09e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PTEN—head and neck cancer	1.75e-05	3.04e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NOTCH1—head and neck cancer	1.75e-05	3.03e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—AKT1—head and neck cancer	1.74e-05	3.02e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—AKT1—head and neck cancer	1.74e-05	3.01e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—AKT1—head and neck cancer	1.73e-05	3e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TP53—head and neck cancer	1.72e-05	3e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—AKT1—head and neck cancer	1.72e-05	2.99e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MAPK1—head and neck cancer	1.71e-05	2.98e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—EGFR—head and neck cancer	1.71e-05	2.98e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—IL2—head and neck cancer	1.7e-05	2.95e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PTEN—head and neck cancer	1.7e-05	2.95e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NOTCH1—head and neck cancer	1.69e-05	2.94e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—HRAS—head and neck cancer	1.69e-05	2.94e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—AKT1—head and neck cancer	1.68e-05	2.92e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—HRAS—head and neck cancer	1.68e-05	2.92e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—AKT1—head and neck cancer	1.68e-05	2.91e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—PIK3CA—head and neck cancer	1.67e-05	2.9e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—HRAS—head and neck cancer	1.66e-05	2.89e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—HRAS—head and neck cancer	1.65e-05	2.86e-05	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—AKT1—head and neck cancer	1.65e-05	2.86e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—MAPK3—head and neck cancer	1.64e-05	2.84e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL2—head and neck cancer	1.63e-05	2.83e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—AKT1—head and neck cancer	1.62e-05	2.81e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PTEN—head and neck cancer	1.61e-05	2.8e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—AKT1—head and neck cancer	1.61e-05	2.8e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—STAT3—head and neck cancer	1.61e-05	2.8e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—VEGFA—head and neck cancer	1.61e-05	2.79e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—PIK3CA—head and neck cancer	1.61e-05	2.79e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL2—head and neck cancer	1.6e-05	2.78e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—BCL2—head and neck cancer	1.6e-05	2.78e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—STAT3—head and neck cancer	1.59e-05	2.76e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—AKT1—head and neck cancer	1.59e-05	2.76e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CCND1—head and neck cancer	1.59e-05	2.76e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—STAT3—head and neck cancer	1.56e-05	2.72e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CCND1—head and neck cancer	1.56e-05	2.71e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—MAPK1—head and neck cancer	1.56e-05	2.7e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—EGFR—head and neck cancer	1.56e-05	2.7e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HRAS—head and neck cancer	1.55e-05	2.68e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PIK3CA—head and neck cancer	1.54e-05	2.68e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL2—head and neck cancer	1.54e-05	2.68e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—MAPK3—head and neck cancer	1.54e-05	2.67e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PTEN—head and neck cancer	1.53e-05	2.66e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MAPK3—head and neck cancer	1.52e-05	2.64e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—STAT3—head and neck cancer	1.52e-05	2.63e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PTEN—head and neck cancer	1.51e-05	2.62e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—MAPK3—head and neck cancer	1.49e-05	2.59e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—AKT1—head and neck cancer	1.49e-05	2.59e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—PIK3CA—head and neck cancer	1.49e-05	2.58e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—HRAS—head and neck cancer	1.49e-05	2.58e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—AKT1—head and neck cancer	1.48e-05	2.58e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—AKT1—head and neck cancer	1.47e-05	2.55e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—MAPK1—head and neck cancer	1.46e-05	2.54e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EGFR—head and neck cancer	1.46e-05	2.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—AKT1—head and neck cancer	1.46e-05	2.53e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—MAPK3—head and neck cancer	1.45e-05	2.52e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MAPK1—head and neck cancer	1.45e-05	2.51e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EGFR—head and neck cancer	1.45e-05	2.51e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—STAT3—head and neck cancer	1.44e-05	2.51e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—head and neck cancer	1.44e-05	2.5e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—HRAS—head and neck cancer	1.43e-05	2.48e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—MAPK1—head and neck cancer	1.42e-05	2.47e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EGFR—head and neck cancer	1.42e-05	2.47e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL2—head and neck cancer	1.41e-05	2.45e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTGS2—head and neck cancer	1.4e-05	2.44e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—VEGFA—head and neck cancer	1.38e-05	2.4e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MAPK3—head and neck cancer	1.38e-05	2.4e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—MAPK1—head and neck cancer	1.38e-05	2.39e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EGFR—head and neck cancer	1.38e-05	2.39e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—HRAS—head and neck cancer	1.38e-05	2.39e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—STAT3—head and neck cancer	1.37e-05	2.38e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—AKT1—head and neck cancer	1.37e-05	2.37e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—VEGFA—head and neck cancer	1.36e-05	2.36e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—PIK3CA—head and neck cancer	1.35e-05	2.34e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—STAT3—head and neck cancer	1.35e-05	2.34e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PTEN—head and neck cancer	1.33e-05	2.3e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NOTCH1—head and neck cancer	1.32e-05	2.3e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MAPK1—head and neck cancer	1.31e-05	2.28e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EGFR—head and neck cancer	1.31e-05	2.28e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—AKT1—head and neck cancer	1.31e-05	2.28e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MAPK3—head and neck cancer	1.31e-05	2.27e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MAPK3—head and neck cancer	1.29e-05	2.23e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—PIK3CA—head and neck cancer	1.27e-05	2.21e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—AKT1—head and neck cancer	1.26e-05	2.19e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PIK3CA—head and neck cancer	1.26e-05	2.18e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HRAS—head and neck cancer	1.25e-05	2.17e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MAPK1—head and neck cancer	1.25e-05	2.16e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EGFR—head and neck cancer	1.24e-05	2.16e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—MAPK3—head and neck cancer	1.24e-05	2.15e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL2—head and neck cancer	1.24e-05	2.15e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PIK3CA—head and neck cancer	1.23e-05	2.14e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MAPK1—head and neck cancer	1.22e-05	2.13e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EGFR—head and neck cancer	1.22e-05	2.13e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTEN—head and neck cancer	1.22e-05	2.12e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—AKT1—head and neck cancer	1.22e-05	2.11e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—head and neck cancer	1.21e-05	2.11e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCND1—head and neck cancer	1.21e-05	2.1e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL2—head and neck cancer	1.2e-05	2.09e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PIK3CA—head and neck cancer	1.2e-05	2.08e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NAT2—head and neck cancer	1.19e-05	2.07e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—STAT3—head and neck cancer	1.19e-05	2.06e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—MAPK1—head and neck cancer	1.18e-05	2.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—EGFR—head and neck cancer	1.18e-05	2.05e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HRAS—head and neck cancer	1.18e-05	2.04e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCND1—head and neck cancer	1.17e-05	2.03e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL2—head and neck cancer	1.17e-05	2.02e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PTEN—head and neck cancer	1.16e-05	2.02e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HRAS—head and neck cancer	1.16e-05	2.02e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HRAS—head and neck cancer	1.14e-05	1.98e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PIK3CA—head and neck cancer	1.14e-05	1.98e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCND1—head and neck cancer	1.14e-05	1.97e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MAPK3—head and neck cancer	1.13e-05	1.97e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PTEN—head and neck cancer	1.13e-05	1.96e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—PIK3CA—head and neck cancer	1.13e-05	1.96e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HRAS—head and neck cancer	1.11e-05	1.92e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—AKT1—head and neck cancer	1.1e-05	1.92e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PTEN—head and neck cancer	1.1e-05	1.9e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—STAT3—head and neck cancer	1.09e-05	1.9e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PIK3CA—head and neck cancer	1.08e-05	1.88e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MAPK1—head and neck cancer	1.08e-05	1.87e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EGFR—head and neck cancer	1.08e-05	1.87e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PIK3CA—head and neck cancer	1.06e-05	1.85e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HRAS—head and neck cancer	1.05e-05	1.83e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VEGFA—head and neck cancer	1.05e-05	1.83e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—DPYD—head and neck cancer	1.05e-05	1.82e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MAPK3—head and neck cancer	1.05e-05	1.82e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—head and neck cancer	1.05e-05	1.82e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—STAT3—head and neck cancer	1.04e-05	1.81e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—AKT1—head and neck cancer	1.04e-05	1.8e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—head and neck cancer	1.03e-05	1.79e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—AKT1—head and neck cancer	1.03e-05	1.78e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—PIK3CA—head and neck cancer	1.02e-05	1.78e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VEGFA—head and neck cancer	1.02e-05	1.77e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—STAT3—head and neck cancer	1.01e-05	1.76e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—AKT1—head and neck cancer	1.01e-05	1.75e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HRAS—head and neck cancer	1e-05	1.74e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAPK3—head and neck cancer	9.95e-06	1.73e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MAPK1—head and neck cancer	9.95e-06	1.73e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EGFR—head and neck cancer	9.95e-06	1.73e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—YAP1—head and neck cancer	9.92e-06	1.72e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VEGFA—head and neck cancer	9.9e-06	1.72e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HRAS—head and neck cancer	9.83e-06	1.71e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—STAT3—head and neck cancer	9.81e-06	1.7e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—AKT1—head and neck cancer	9.77e-06	1.7e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAPK3—head and neck cancer	9.66e-06	1.68e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAPK1—head and neck cancer	9.47e-06	1.64e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HRAS—head and neck cancer	9.47e-06	1.64e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EGFR—head and neck cancer	9.47e-06	1.64e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAPK3—head and neck cancer	9.37e-06	1.63e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PIK3CA—head and neck cancer	9.35e-06	1.62e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—AKT1—head and neck cancer	9.3e-06	1.62e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—AKT1—head and neck cancer	9.2e-06	1.6e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAPK1—head and neck cancer	9.19e-06	1.6e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EGFR—head and neck cancer	9.19e-06	1.6e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL2—head and neck cancer	9.11e-06	1.58e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAPK1—head and neck cancer	8.92e-06	1.55e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EGFR—head and neck cancer	8.91e-06	1.55e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCND1—head and neck cancer	8.88e-06	1.54e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—AKT1—head and neck cancer	8.83e-06	1.53e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—AKT1—head and neck cancer	8.68e-06	1.51e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HRAS—head and neck cancer	8.65e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3CA—head and neck cancer	8.63e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTEN—head and neck cancer	8.57e-06	1.49e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—AKT1—head and neck cancer	8.36e-06	1.45e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CA—head and neck cancer	8.22e-06	1.43e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HRAS—head and neck cancer	7.99e-06	1.39e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CA—head and neck cancer	7.98e-06	1.39e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—head and neck cancer	7.95e-06	1.38e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VEGFA—head and neck cancer	7.74e-06	1.34e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CA—head and neck cancer	7.74e-06	1.34e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—head and neck cancer	7.72e-06	1.34e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—STAT3—head and neck cancer	7.66e-06	1.33e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—AKT1—head and neck cancer	7.64e-06	1.33e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HRAS—head and neck cancer	7.6e-06	1.32e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—head and neck cancer	7.48e-06	1.3e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HRAS—head and neck cancer	7.38e-06	1.28e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK3—head and neck cancer	7.32e-06	1.27e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HRAS—head and neck cancer	7.16e-06	1.24e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—AKT1—head and neck cancer	7.05e-06	1.22e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK1—head and neck cancer	6.97e-06	1.21e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGFR—head and neck cancer	6.96e-06	1.21e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—AKT1—head and neck cancer	6.71e-06	1.17e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AKT1—head and neck cancer	6.52e-06	1.13e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AKT1—head and neck cancer	6.32e-06	1.1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CA—head and neck cancer	6.04e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TYMS—head and neck cancer	5.96e-06	1.03e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTM1—head and neck cancer	5.89e-06	1.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—head and neck cancer	5.85e-06	1.02e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GPX1—head and neck cancer	5.64e-06	9.8e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HRAS—head and neck cancer	5.59e-06	9.71e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP1A1—head and neck cancer	5.58e-06	9.7e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT1—head and neck cancer	4.94e-06	8.57e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—head and neck cancer	3.32e-06	5.77e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTEN—head and neck cancer	2.9e-06	5.03e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CA—head and neck cancer	2.04e-06	3.55e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKT1—head and neck cancer	1.67e-06	2.9e-06	CbGpPWpGaD
